The aim of our study was to compare the prevalence, etiology, and outcomes of sepsis and associated AKI in pre- and post-COVID-19 pandemic.
Methods:
We conducted a retrospective observational analysis in 144 patients with sepsis and AKI, in two periods of time, 2 years before and after COVID-19 pandemic, with 2 years’ washout period.
Results:
The comparative analysis between the two periods demonstrated more severe forms of sepsis with septic shock dominating in the post pandemic period (5 (10%) vs 23 (25%), p = 0.037). According AKI staging we found AKI stage 3 more frequently present after pandemic and more patients needed dialysis in the post COVID-19 pandemic (35 (70%) vs 79 (84%), p = 0.04; 31 (62%) vs 78 (54%), p = 0.02; 16 (32%) vs 51% (54%), p = 0.018), respectively. Patients in post COVID-19 era survived less longer (22.66 ± 11.32 vs 17.132 ± 12.66, p = 0.021) with almost doubled risk for mortality HR: 1.977; 95% CI (1.127 ± 3.469), p = 0.018. Regarding causative agents’ there was similar distribution in both periods, but the multiple antibiotic resistance index (MAR) was significantly higher in the post COVID-19 period for Staphylococcus coagulase negative (0.48 vs 0.62, p = 0.001).
Conclusion:
Sepsis and associated AKI occurrence, morbidity and mortality are significantly higher in the post COVID-19 pandemic and the increased MAR of the germs can be one of the main reason for it.
WHO. WHO COVID-19 dashboard (including Macedonia (monthly bulletin on the movement of infectious diseases for July 2025, Bilten 7_2025.pdf)), https://data.who.int/dashboards/covid19/summary (2025, accessed 9 August 2025).
DavisHEMcCorkellLVogelJM, et al. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol2023; 21: 133–146.
5.
MunkPBrinchCMøllerFD, et al. Genomic analysis of sewage from 101 countries reveals global landscape of antimicrobial resistance. Nat Commun2022; 13: 7251.
MellhammarLWollterEDahlbergJ, et al. Estimating sepsis incidence using administrative data and clinical medical record review. JAMA Netw Open2023; 6(8): e2331168.
8.
SprungCLScheinRMHBalkRA.The new sepsis consensus definitions: the good, the bad and the ugly. Intensive Care Med2016; 42: 2024–2026.
9.
KellumJAChawlaLSKeenerC, et al. The effects of alternative resuscitation strategies on acute kidney injury in patients with septic shock. Am J Respir Crit Care Med2016; 193(3): 281–287.
10.
RuddKEJohnsonSCAgesaKM, et al. Global, regional, and national sepsis incidence and mortality, 1990–2017: analysis for the Global Burden of Disease Study. Lancet2020; 395(10219): 200–211.
11.
SingerMDeutschmanCSSeymourCW, et al. The third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA2016; 315(8): 801–810.
12.
MartinGS.Sepsis, severe sepsis and septic shock: changes in incidence, pathogens and outcomes. Expert Rev Anti Infect Ther2012; 10(6): 701–706.
13.
AyandeleAAOladipoEKOyebisiO, et al. Prevalence of multi-antibiotic resistant Escherichia coli and Klebsiella species obtained from a Tertiary Medical Institution in Oyo State, Nigeria. Qatar Med J2020; 2020(1): 9.
14.
Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl2012; 2: 1–138.
15.
ForniLGDarmonMOstermannM, et al. Renal recovery after acute kidney injury. Intensive Care Med2017; 43(6): 855–866.
16.
La ViaLSangiorgioGStefaniS, et al. The global burden of sepsis and septic shock. Epidemiologia2024; 5(3): 456–478.
17.
AlRahmounMSabaté-ElabbadiAGuillemotD, et al. Impacts of the COVID-19 pandemic on sepsis incidence, etiology and hospitalization costs in France: a retrospective observational study. BMC Infect Dis2024; 25(1): 627.
18.
KnightGMGloverREMcQuaidCF, et al. Antimicrobial resistance and COVID-19: intersections and implications. Elife2021; 10: e64139.
19.
KratzerBGattingerPTrapinD, et al. Differential decline of SARS-CoV-2-specific antibody levels, innate and adaptive immune cells, and shift of Th1/inflammatory to Th2 serum cytokine levels long after first COVID-19. Allergy2024; 79(9): 2482–2501.
20.
LageSLBricker-HoltKRoccoJM, et al. Persistent immune dysregulation and metabolic alterations following SARS-CoV-2 infection. medRxiv [Preprint]. 2025 Apr 17:2025.04.16.25325949. doi:10.1101/2025.04.16.25325949. PMID:40321289; PMCID:PMC12047922
21.
KarimMMAkhterSKarimS.Thrombocytopenia in post Covid era: puzzle in the diagnosis. Bangladesh J Med2024; 35(20): 147–148.
22.
RanucciMBaryshnikovaEAnguissolaM, et al. The long term residual effects of COVID-associated coagulopathy. Int J Mol Sci2023; 24(6): 5514.
23.
MehandruSMeradM.Pathological sequelae of long-haul COVID. Nat Immunol2022; 23: 194–202.
24.
Van RampelberghRPavordSAnaya-VelardeL, et al. Comparison of vaccine-induced immune thrombocytopenia and thrombosis cases following two adenovirus-vectored COVID-19 vaccines. Commun Med2025; 5: 168.
25.
ChengJZengHChenH, et al. Current knowledge of thrombocytopenia in sepsis and COVID-19. Front Immunol2023; 14: 1213510.
26.
SchuppTWeidnerKRusnakJ, et al. Diagnostic and prognostic role of platelets in patients with sepsis and septic shock. Platelets2023; 34(1): 2131753.
27.
UnterbergMRahmelTRumpK, et al. The impact of the COVID-19 pandemic on non-COVID induced sepsis survival. BMC Anesthesiol2022; 22: 12.
28.
LiKWeiYHungCT, et al. Post-pandemic excess mortality of COVID-19 in Hong Kong: a retrospective study. Lancet Reg Health West Pac2025; 58: 101554.
29.
KakeyaHNittaTKamijimaY, et al. Significant increase in excess deaths after repeated COVID-19 vaccination in Japan. JMA J2025; 8(2): 584–586.
30.
Pearson-StuttardJCaulSMcDonaldS, et al. Excess mortality in England post COVID-19 pandemic: implications for secondary prevention. Lancet Reg Health Eur2023; 36: 100802.
LiYGuoJYangH, et al. Comparison of culture-negative and culture-positive sepsis or septic shock: a systematic review and meta-analysis. Crit Care2021; 25(1): 167.
34.
RhodesAEvansLEAlhazzaniW, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med2017; 43(3): 304–377.
35.
Abdelaziz AbdelmoneimSMohamed GhazyRAnwar SultanE, et al. Antimicrobial resistance burden pre and post-COVID-19 pandemic with mapping the multidrug resistance in Egypt: a comparative cross-sectional study. Sci Rep2024; 14(1): 7176.
36.
FalascaKVetrugnoLBorrelliP, et al. Antimicrobial resistance in intensive care patients hospitalized with SEPSIS: a comparison between the COVID-19 pandemic and pre-pandemic era. Front Med2024; 11: 1355144.
37.
PeconiCMartiniESartiD, et al. Impact of the COVID-19 pandemic on healthcare-associated infections and multidrug-resistant microorganisms in Italy: a systematic review. J Infect Public Health2025; 18(5): 102729.
38.
Centers for Disease Control and Prevention (U.S.). COVID-19 reverses progress in fight against antimicrobial resistance in U.S.: hospitalization related infections grew 15% from 2019 to 2020: media statement for immediate release: Tuesday, July 12, 2022. CDC, 2022, https://stacks.cdc.gov/view/cdc/119024 (accessed 10 December 2025).
